A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-na ïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)
Condition: Gastric Cancer Interventions: Drug: ONO-4538; Drug: Ipilimumab; Drug: Oxaliplatin; Drug: Capecitabine; Drug: S-1 Sponsor: Ono Pharmaceutical Co. Ltd Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Chemotherapy | Eloxatin | Gastric (Stomach) Cancer | Gastroenterology | HER2 | Research | Study | Xeloda | Yervoy